New Drug Down Under Helps Ease Pressure of PAH

In December 2015, the U.S. Food and Drug Administration approved Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (or PAH).

Now, others around the world will have the same option. On March 17th and 18th, 2016, Medsafe and the TGA approved Uptravi for use in New Zealand and Australia, respectively.

In people with pulmonary arterial hypertension, blood vessels between the heart and lungs are constricted, elevating blood pressure and complicating blood flow to the lungs.

By combining with prostacyclin receptors in the body, Uptravi–an oral medication–helps to relax muscles in the walls of blood vessels, thereby widening passageways and decreasing pressure.

The most common side effects reported with Uptravi include headache, diarrhea, nausea, vomiting, muscle pain, joint pain, pain in extremities, jaw pain, and flushing.

James Ernest Cassady

James Ernest Cassady

Though "Ernest" is a family name that's been passed down for generations, James truly earned his middle moniker when, at the age of five, he told his mother that "laughing is stupid unless EVERYBODY is happy." Since then, the serious little bastard has been on a mission to highlight the world's shortcomings (and hopefully correct them). In addition to his volunteer work at hospitals and animal shelters, James also enjoys documentaries and the work of William Faulkner. He is originally from Oklahoma.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email